Antinuclear Antibody (HEp-2) Substrate Slide

  • Applications
    • IF
  • Code # AN-1016
  • Size 16 wells
  • Price Call for Price
Specifications

Background

Antinuclear antibodies (ANA) are a group of autoantibodies characterized by specificity for numerous antigenic determinants of cell nuclei. While the role of ANA’s in the pathogenesis of autoimmune disease is controversial, they are quite useful as disease markers, primarily for diagnostic screening and also to monitor the course of connective tissue diseases. Because of the high correlation of positive antinuclear antibodies with SLE a negative ANA essentially rules out this disease. Although antibodies specific to DNA have a high correlation with SLE, antibodies to a number of other nuclear antigens appear to be of diagnostic and/or prognostic significance in diseases such as Progressive Systemic Sclerosis, Mixed Connective Tissue Disease, Sjogren's Syndrome, and Polymyositis; making ANA testing useful not only for SLE, but as a general screening tool for connective tissue diseases.

  • Application:
    IF
  • Components:

    The MBL Bion ANA ANTIGEN SUBSTRATE SLIDES are individually foil wrapped slides of 16 wells with HEp-2 tissue culture cells fixed onto each well.

  • Description:

    The antigen of the MBL Bion ANA substrate is a human epithelial cell (HEp-2) line. HEp-2 cells have been shown to have greater sensitivity than tissue sections and aid in sharper differential pattern recognition as well as detecting previously unreported nuclear antibodies.

    •  Each lot is tested with a panel of titered control sera to ensure sensitivity from lot to lot
    •  Each lot is tested for pattern types, and for specific antinuclear antibodies
    •  Mitotic cells are present for detection of centromere antibodies; also helps to identify other patterns
    •  Substrate is sensitive for detection of low titered specific antibodies
    •  Substrate is specific for detection of SS-A and other antibodies

     INTENDED USE

    The MBL Bion ANA (HEp-2) ANTIGEN SUBSTRATE SLIDES may be used as the antigenic substrate in indirect fluorescent antibody assays for the qualitative and/or semi-quantitative determination of antinuclear antibodies in human serum. MBL Bion ANA (HEp-2) ANTIGEN SUBSTRATE SLIDES are intended for use as an aid in the diagnosis of certain autoimmune diseases.

  • Product Type:
    Antigen Substrate Slide
  • Research Area:
    Autoimmune
  • Short Description:

    Antigen substrate slides used in indirect fluorescent antibody assays.

  • Size:
    16 wells
References
  1. Tan, E., AntinuclearAntibodies: Diagnostic Markers for Autoimmune Diseases and Probes forCell Biology,Adv. Immuno., 44:93-151, 1989.
  2. Nakamura, R., C. Peebles, R. Rubin, et al, Autoantibodies to Nuclear Antigens, 2nd ed.,ASCP, Chicago, 1985.
  3. Tan, E., E. Chan, K. Sullivan, et al,AntinuclearAntibodies (ANA’s): Diagnostically Specific Immune Markers and Clues Toward the Understanding of SystemicAutoimmunity, Clin. Immunol.Immunopathol., 47:121-141, 1988.
  4. Barnett, E.V.,AntinuclearAntibodies and NuclearAntigens, California Medicine, 104:463-469, 1966.
  5. Casals, S.P., G.J. Friou, L.L. Meyers, Significance ofAntibody to DNA in Systemic Lupus Erythematosus, Arth. Rheum., 7:379-390, 1964.
  6. Douvas, A.S., M. Achten, E.M. Tan, Identification of a Nuclear Protein (Scl-70) as a Unique Target of HumanAntinuclearAntibodies in Scleroderma, J. Biol. Chem., 244:10514-10522, 1979.
  7. Moroi, Y., C. Peebles, M.J. Fritzler, et al, Autoantibody to Centromere (Kinetochore) in Scleroderma Sera, Proc. Natl. Acad. Sci., 77:1627-1631, 1980. Sharp, G.C., W.S. Irwin, E.M. Tan, et al, Mixed Connective Tissue Disease - An Apparently Distinct Rheumatic Disease Syndrome Associated with a SpecificAntibody to an Extractable Nuclear Antigen (ENA), Am. J. Med., 52:148-159, 1972.
  8. Alsaugh, M.A., W. Talal, E.M. Tan, Differentiation and Characterization ofAutoantibodies and their Antigens in Sjogrens Syndrome, Arth. Rheum., 19:216-222, 1976.
  9. Wolfe, J.F., E.Adelstein, G.C. Sharp,AntinuclearAntibody with Distinct Specificity for Polymyositis, J. Clin. Invest., 59:176-178, 1977.
  10. Nakamura, R.M., C.L. Peebles, D.P. Molden, E.M. Tan, Advances in Laboratory Tests for Autoantibodies to NuclearAntigens in Systemic Rheumatic Diseases, Lab. Med., 15:190-198, 1984.
  11. Moore, A.E., L. Sabachewsky, H.W. Toolan, Culture Characteristics of Four Permanent Lines of Human Cells, Cancer Res., 15:598-602, 1955.
  12. McCarty, G.A., J.R. Rice, Characterization and Comparison of Commercially Available Antinuclear Antibody Kits Using Single Pattern Index Sera, J. Rheum., 7:339-347, 1980.
  13. McCarty, G.A., et al,AUnique AntinuclearAntibody Staining Only the Mitotic Spindle Apparatus, New Engl. J. Med., 305:703, 1981.
  14. Miyachi, K., M.J. Fritzler, E.M. Tan, Autoantibody to a NuclearAntigen in Proliferating Cells, J. Immunol., 121:2228-2234, 1978.
  15. Schur, P.H., M. Moore, N. Rothfield, The Subclass ofAntinuclear andAntinucleic Acid Antibodies, Arth. Rheum., 15:174-180, 1972.
  16. Weller, T.H., A.H. Coons, Fluorescent Antibody Studies with Agents of Varicella and Herpes Zoster Propagated InVitro, Proc. Soc. Exp. Biol. Med., 86:789-794, 1954.18. Friou, F.J., ClinicalApplication of Lupus Serum-Nucleoprotein Reaction Using the FluorescentAntibody Technique,J. Clin. Invest., 36:890, 1957.
  17. Holman, H.R., H.G. Kunkel, Affinity Between the Lupus Erythematosus Serum Factor and Cell Nuclei and Nucleoprotein, Science, 126:162-163, 1957.
  18. Lyerla, H.C., F.T. Forrester, The Immunofluorescence (IF) Test, in Immunofluorescence Methods in Virology, USDHHS, Georgia, 71-81, 1979.
  19. Peter, J.B., R.L. Dawkins, EvaluatingAutoimmune Diseases, Diag. Med., 1-10, Sept/Oct 1979.
  20. Notman, D.D., N. Kurata, E.M. Tan, Profiles ofAntinuclear Antibodies in Systemic Rheumatic Diseases, Annals Intern. Med., 83:464-469, 1975.
  21. Nakamura, R.M., C.L. Peebles, R.L. Rubin, et al, Autoantibodies to Nuclear Antigens (ANA),ASCP, Chicago, 1985.
  22. Molden, D.P., ANAProfiles in Systemic Rheumatic Disease, Diag. Med., 12-18, June 1985.
  23. Fritzler, M.J., D.W. Valencia, G.A. McCarty, Speckled PatternAntinuclearAntibodies Resembling Anticentromere Antibodies, Arth. Rheum., 27(l):92-96, 1984.
  24. Fritzler, M.J., T.D. Kinsella, E. Garbutt, The CREST Syndrome: A Distinct Serologic Entity with Anticentromere Antibodies, Am. J. Med., 69:520-526, 1980.
  25. Tan, E.M., G.P. Rodnan, I. Garcia, et al, Diversity of Antinuclear Antibodies in Progressive Systemic Sclerosis, Arth. Rheum., 23:617-625, 1980.
  26. Penning, C., V. Steen, G. Reimer, et al, An Analysis of Systemic Sclerosis Patients with Autoantibodies to the Nucleolar Proteins PM-Scl, RNAPolymerase I and Fibrillarin,A.R.A. Mtg., D29, 1987.
  27. Pinnas, J.L., J.D. Northway, E.M. Tan, Antinucleolar Antibodies in Human Sera, J. Immunol., 111:996-1004, 1973.
  28. Ritchie, R.F.,AntinucleolarAntibodies: Their Frequency and DiagnosticAssociation, New Engl. J. Med., 282:1174-1178, 1970.
  29. Bianchi, F.B., M. Rizzetto, P. Penfold, et al, Ultrastructural Localization and Characterization of a Ribosomal Antibody Detected by Immunofluorescence in Systemic Lupus Erythematosus, Clin. Exp. Immunol., 17:629-636, 1974.
  30. Rothfield, N.F., Detection ofAntibodies to NuclearAntigens by Immunofluorescence, Manual of Clinical Immunology, ASM, Washington D.C., 85:647-651, 1976.
  31. Pollack, V.E., AntinuclearAntibodies in Families of Patients with Systemic Lupus Erythematosus, New Engl. J. Med.,271:165-171, 1964.
  32. Tan, E.M., M.J. Fritzler, P.A. Reyes-Lopez, Autoantibodies as Biological Markers of Neoplasia: Basic and Applied Aspects, Elsevier-North Holland, New York, 1978.
  33. Cleymaet, J.E., R.M. Nakamura, Indirect ImmunofluorescentAntinuclearAntibody Tests: Comparison of Sensitivity and Specificity of Different Substrates, Am. J. Clin. Path., 58:388-393, 1972.
  34. Data on file, MBL Bion, Des Plaines, Illinois.